Ultragenyx Pharmaceutical Inc.
RARE
$26.96
$0.160.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 57.35% | -34.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 57.35% | -34.39% | |||
| Cost of Revenue | 6.35% | -18.75% | |||
| Gross Profit | 124.53% | -109.11% | |||
| SG&A Expenses | 2.33% | -2.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.09% | -14.21% | |||
| Operating Income | 46.04% | -22.70% | |||
| Income Before Tax | 50.54% | -44.10% | |||
| Income Tax Expenses | 0.00% | 14.94% | |||
| Earnings from Continuing Operations | 50.27% | -43.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 50.27% | -43.91% | |||
| EBIT | 46.04% | -22.70% | |||
| EBITDA | 48.85% | -25.36% | |||
| EPS Basic | 50.91% | -42.91% | |||
| Normalized Basic EPS | 41.67% | -20.26% | |||
| EPS Diluted | 50.91% | -42.91% | |||
| Normalized Diluted EPS | 41.67% | -20.26% | |||
| Average Basic Shares Outstanding | 1.29% | 0.70% | |||
| Average Diluted Shares Outstanding | 1.29% | 0.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||